scholarly journals Microsatellite instability in Gastric Cancer: Between lights and shadows

2021 ◽  
Vol 95 ◽  
pp. 102175
Author(s):  
Elisabetta Puliga ◽  
Simona Corso ◽  
Filippo Pietrantonio ◽  
Silvia Giordano
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability

Activin a Receptor Type 2A Mutation Affects the Tumor Biology of Microsatellite Instability-High Gastric Cancer

2021 ◽  
Author(s):  
Kizuki Yuza ◽  
Masayuki Nagahashi ◽  
Hiroshi Ichikawa ◽  
Takaaki Hanyu ◽  
Masato Nakajima ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Tumor Biology ◽  
Activin A ◽  
Receptor Type

Microsatellite frameshift variants in SGO1 of gastric cancer are not always associated with MSI status

2020 ◽  
pp. jclinpath-2020-206934
Author(s):  
Tomohiro Sugiyama ◽  
Moriya Iwaizumi ◽  
Terumi Taniguchi ◽  
Satoshi Suzuki ◽  
Shinya Tani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Mismatch Repair ◽  
Gastrointestinal Cancer ◽  
Early Stage ◽  
Stage Iv ◽  
Cancer Resection ◽  
Deficient Mismatch Repair ◽  
Gastric Cancer Resection ◽  
Genemapper Software

AimsAlthough frameshift variants in the microsatellite area of shugoshin 1 (SGO1) have been reported in the context of microsatellite instability-high (MSI-H)/deficient mismatch repair gastrointestinal cancer, most have been evaluated only in early stage I–III patients, and only two of its five microsatellite regions have been evaluated. Therefore, we investigated the frequency and MSI status of microsatellite frameshift variants in gastric cancer cases, including stage IV.MethodsIn a total of 55 cases, 30 gastric cancer resection and 25 non-resection cases, DNA was extracted from both tumour and normal parts and PCR was performed. The variant was confirmed by TA cloning, and MSI was evaluated using GeneMapper software.ResultsA frameshift variant of c.973delA was observed in 16 of the 45 evaluable cases. Its frequency was 35.6%. Of the 25 cases that could be assessed for MSI status, two cases of MSI-H were associated with the c.973delA SGO1 variant. However, c.973delA SGO1 variant was also observed in four cases of microsatellite stable.ConclusionOur study shows that SGO1 frameshift variants are not always associated with MSI status.

scholarly journals Infrequent loss of heterozygosity of APC/MCC and DCC genes in gastric cancer showing DNA microsatellite instability

1999 ◽  
Vol 52 (7) ◽  
pp. 504-508 ◽  
Author(s):  
D. C. Fang ◽  
J. R. Jass ◽  
D. X. Wang ◽  
X. D. Zhou ◽  
Y. H. Luo ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Loss Of Heterozygosity ◽  
Dna Microsatellite

Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study

2021 ◽  
Author(s):  
Namkee Oh ◽  
Hyunki Kim ◽  
Kyoung-Mee Kim ◽  
Jae-Ho Cheong ◽  
Jeeyun Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Adjuvant Treatment

scholarly journals Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Xinyu Li ◽  
Lan Zhang ◽  
Chunxiao Wang ◽  
Junli Huang ◽  
Jinfeng Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Clinical Characteristics

Familial aggregation of gastric cancer with microsatellite instability*

2018 ◽  
Vol 118 (5) ◽  
pp. 287-293 ◽  
Author(s):  
Karol Polom ◽  
Daniele Marrelli ◽  
Costantino Voglino ◽  
Giandomenico Roviello ◽  
Lorenzo De Franco ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability ◽  
Familial Aggregation

Marked Differences in The Frequency of Microsatellite Instability in Gastric Cancer From Different Countries

1999 ◽  
Vol 94 (10) ◽  
pp. 3034-3038 ◽  
Author(s):  
Antonia R Sepulveda ◽  
Ana C Santos ◽  
Yoshio Yamaoka ◽  
Ling Wu ◽  
Oscar Gutierrez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Microsatellite Instability

The interaction between microsatellite instability high (MSI-high) gastric cancer and chemotherapy on survival.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 244-244
Author(s):  
Elvira Lise Vos ◽  
Steven Brad Maron ◽  
Robert Wallace Krell ◽  
Masaya Nakauchi ◽  
Megan Fiasconaro ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemotherapy ◽  
Microsatellite Instability ◽  
Locally Advanced ◽  
Multivariable Analysis ◽  
Tumor Stage ◽  
High Status ◽  
High Group ◽  
Locally Advanced Gastric Cancer

244 Background: Subgroup analysis of trials data suggested a favorable prognostic role for microsatellite instability high (MSI-high) status in resectable gastric cancer, but a lack of survival benefit from neoadjuvant/adjuvant chemotherapy; questioning current standard of care for MSI-high locally advanced gastric cancer. To help guide treatment decision making, we retrospectively studied the interaction between MSI status and chemotherapy on survival in a single institution. Methods: All clinically advanced (tumor stage 3-4 or positive lymph nodes) gastric cancer patients that underwent gastrectomy between 2000-2018 with MSI status available from immunohistochemistry (IHC, deficient mismatch repair protein expression (dMMR) vs proficient (pMMR)) or DNA next generation sequencing testing (NGS, MSI-high vs low/stable (MSS)) were included. Clinicopathological characteristics and overall survival (OS) was compared between patients with neoadjuvant/adjuvant chemotherapy and without, stratified for MSI status, by Kaplan-Meier and Cox regression analysis. Results: From a total of 1,844 clinically advanced patients with resection, MSI status was available in 559 as determined by IHC in 420, NGS in 88, and both in 51 with a concordance rate of 50/51 (98%). Tumors were dMMR/MSI-high in 84 (15%) and pMMR/MSS in 475 (85%). Patients with dMMR/MSI-high tumors were more often older, female, and had distal tumors with intestinal subtype. Neoadjuvant and/or adjuvant chemotherapy was administered in 53 (63%) in the dMMR/MSI-high group and 367 (77%) in the pMMR/MSS (p = 0.006). Median (interquartile range) time of follow-up was 32 (19-57) months. In the total cohort, OS after 3 years was 82% in the dMMR/MSI-high and 59% in pMMR/MSS (p < 0.001). In the patients with neoadjuvant/adjuvant chemotherapy only, the dMMR/MSI-high had improved OS (3-years OS: 80% vs 60%, p = 0.001), and after adjustment for age and clinical tumor stage in multivariable analysis, dMMR/MSI-high status was associated with improved OS (HR 0.38 95%CI 0.22-0.68). In the dMMR/MSI-high group only, 3-year OS was 80% with chemotherapy vs 86% without (p = 0.374), and chemotherapy was not associated with a difference in OS after multivariable analysis (HR 1.03 95%CI 0.40-2.66). In case of neoadjuvant chemotherapy, grade 1 pathological response ( > 90%) was observed in 1/41 (2.4%) of the dMMR/MSI-high tumors vs 43/278 (16%) of the pMMR/MSS tumors respectively (p = 0.026). Conclusions: The incidence of MSI-high tumors in our cohort of clinically locally advanced, resectable, gastric cancers was 15%. Patients with MSI-high tumors had worse pathological treatment response to neoadjuvant chemotherapy, but better OS, compared to microsatellite stable tumors. However, in patients with MSI-high tumors, OS was not altered by neoadjuvant/adjuvant chemotherapy. We recommend assessing MSI status in locally advanced gastric cancer.

Sign in / Sign up

Export Citation Format

Share Document